Research study of QOL with leukotriene receptor antagonist ,pranlukast in asthmatic patients by use of Asthma Health Questionnaire-Japan QOL (AHQ-JAPAN QOL)

Research study of QOL with leukotriene receptor antagonist ,pranlukast in asthmatic patients by use of Asthma Health Questionnaire-Japan QOL (AHQ-JAPAN QOL) - Asthma QOL Research Study by use of Asthma Health Questionnaire-Japan QOL (AHQ-JAPAN QOL)

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000000724

Enrollment

1500

Registered

2007-06-01

Start date

2004-10-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Asthma

Interventions

Pranlukast 2 tablets x 2 / day (112.5mg/tablet) 8 weeks

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Asthmatic patients with mild-to-severe asthma (as defined by the Japanese Society of Allergology) that were not well controlled by daily treatment.

Exclusion criteria

Exclusion criteria: Asthmatic patients with leukotoriene antagonists other than pranlukast.

Design outcomes

Primary

Measure	Time frame
QOL Questionnaire of asthmatic patients by use of AHQ-JAPAN QOL and AQLQ.	—

Secondary

Measure	Time frame
Pulmonary functions test((PEF,FVC and FEV)	—

Countries

Japan

Contacts

Public ContactHiroko Arioka

International Medical Center of Japan Department of Respiratory Disease

harioka@imcj.hosp.go.jp03-3202-7181

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026